]>
IRCT20100413003698N2 IRCT 2018-07-09 Shiraz University of Medical Sciences The role of pentoxifylline in erythropoietin-resistant anemia Evalution the role of pentoxifylline in erythropoietin-resistant anemia in hemodialysis patients 2018-04-04 anticipated 60 Complete https://irct.ir/trial/31491 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: We will collecte 60 patients and randomized into same size groups of trial and control as blocking randomization used for allocation sequence, Blinding description: Double-blind Each patient was given an order number and received the medications in the corresponding prepacked bottles. Patients and who will evaluate the outcome, do not aware of type of drugs. 3 Kidney dialysis. Intervention 1: Intervention group: pentoxifylline. Each patient in the trial group will receive received PTX (400mg twice a day for 12 weeks). Intervention 2: Control group: control group will receive starch tablet twice a day for 12 weeks. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is no additional information
public Maryam Pakfetrat
Internal ward, Nemazi Hospital, Zand street, Shiraz
Shiraz Iran (Islamic Republic of) 11351 – 71937 +98 71 3647 4332 pakfetratm@sums.ac.ir Shiraz University of Medical Sciences scientific Maryam Pakfetrat
floor6, Mohammad Rasool Allah Research Tower, Khalili street, Shiraz, Iran
Shiraz Iran (Islamic Republic of) ۱۴۳۳۶ - ۷۱۳۴۸ +98 176360453 snurc@sums.ac.ir Shiraz University of Medical Sciences Iran (Islamic Republic of) having the age of 18 years and more receiving HD treatments at least for 3 months receiving 4-hour HD treatments 3 times per week a hemoglobin (Hb)<11 in at least 2 consecutive tests in a month no change in EPO dose for at least 1 month before starting the study. 18 years no limit Both blood transfusion due to any reason in recent 3 months Y84.1 Y84 Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure Treatment - Drugs Placebo Intervention group: pentoxifylline. Each patient in the trial group will receive received PTX (400mg twice a day for 12 weeks) Control group: control group will receive starch tablet twice a day for 12 weeks Hemoglobin. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn to measure of hemoglobin. Erythrocyte sedimentation rate. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn. C-reactive protein. Timepoint: at the beginning and the end of the study. Method of measurement: blood samples will be drawn. Shiraz University of Medical Sciences Approved 2017-04-04 Ethical committee of Shiraz University of Medical Sciences floor7-Vice-Chancellery of Research -Shiraz University of Medical Sciences-Zand street- Shiraz Fars Iran (Islamic Republic of)